Please assess the completion status of the following clinical trial:

Trial Title: Blood Biomarkers of Injury and Outcome in Traumatic Brain Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe brain injury (iGCS 12-4 or motor response 2-5 if intubated).~* Age \>18 years (or developmental stage Tanner 5 in patients where age is not known)~* Blunt, traumatic, closed head injury (altered mental status due to brain injury)~* Able to initiate study drug infusion within 4 hours from time of injury -~Exclusion Criteria:~* Non-survivable injury as determined by treating~* Bilateral dilated unresponsive pupils~* Spinal cord injury with neurological deficits, pre-injury paralysis (quad/paraplegic)~* Inability to perform activities of daily living (ADL) without assistance~* Cardiopulmonary arrest~* Status epilepticus on arrival or concern for post ictal state~* systolic blood pressure \< 90 for two consecutive readings at least 5 minutes apart any time prior to randomization~* O2 Sat \< 90 for at least 5 consecutive minutes any time prior to randomization~* Prisoner or ward of state~* Known active breast or reproductive organ cancers (via medical records or family interview)~* Known allergy to progesterone or Intralipid components (egg yolk) (via medical records or family interview)~* Known history of blood clotting disorder (Protein S or C deficiency, etc.) or history of pulmonary embolism (via medical records or family interview) or active/ongoing thromboembolic event (myocardial infarction, ischemic stroke, pulmonary embolism, deep vein thrombosis).~* Blood or serum ethanol (EtOH) ≥ 250 mg %~* Positive qualitative urine or serum pregnancy test~* Concern for inability to follow up at 6 months (residence in foreign country, homeless with limited contacts,~* undocumented immigrants, or high likelihood of becoming incarcerated during study period, etc.)~* Patient in Opt Out registry or wearing Opt Out bracelet -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- On progesterone treatment (Type: None): The group assigned to progesterone treatment.
- group assigned to placebo (Type: None): The group that will not be receiving progesterone treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).